These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 10915243)

  • 1. Required HIV antibody testing, social risk, and HIV-vaccine efficacy trials.
    MacQueen KM; Buchbinder SP; Douglas JM; Judson FN; McKirnan DJ; Bartholow BN
    AIDS Public Policy J; 1996; 11(2):104-12. PubMed ID: 10915243
    [No Abstract]   [Full Text] [Related]  

  • 2. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection.
    MacQueen KM; Buchbinder S; Douglas JM; Judson FN; McKirnan DJ; Bartholow B
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S261-4. PubMed ID: 7865314
    [No Abstract]   [Full Text] [Related]  

  • 3. Willingness to participate in HIV vaccine trials among HIV-negative gay men in Sydney, Australia.
    Van de Ven P; Mao L; Crawford J; Prestage G; Grulich A; Kaldor J; Kippax S
    Int J STD AIDS; 2005 Apr; 16(4):314-7. PubMed ID: 15899086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of homosexual/bisexual men in preventive HIV vaccine trials: baseline attitudes and concerns and predicted behaviors during trials.
    Douglas JM; Judson FN; Parks JP; Buchbinder S; McKirnan D
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S257-60. PubMed ID: 7865313
    [No Abstract]   [Full Text] [Related]  

  • 5. Unique risks to volunteers in HIV vaccine trials.
    Frey SE
    J Investig Med; 2003 Feb; 51 Suppl 1():S18-20. PubMed ID: 12664950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The psychosocial approach to the planning and implementation of vaccine trials for HIV infection].
    Starace F; Embrione F; Fusco ML; Cafaro L
    Ann Ist Super Sanita; 2003; 39(2):259-66. PubMed ID: 14587226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.
    Temoshok LR
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioral studies relevant to vaccine trial preparation: an introduction.
    Turner CF; Sheon AR
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S273-6. PubMed ID: 7865317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domestic AIDS vaccine trials: addressing the potential for social harm to the subjects of human experiments.
    Leider PA
    Calif Law Rev; 2000; 88():1185-232. PubMed ID: 11067733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
    Chesney MA; Lurie P; Coates TJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):30-5. PubMed ID: 7712232
    [No Abstract]   [Full Text] [Related]  

  • 11. Driving the epidemic underground? A new look at law and the social risk of HIV testing.
    Burris S
    AIDS Public Policy J; 1997; 12(2):66-78. PubMed ID: 10915258
    [No Abstract]   [Full Text] [Related]  

  • 12. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention.
    Allen M; Lau CY
    Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to HIV testing and confidentiality: the concerns of HIV-positive and high-risk individuals.
    Solomon L; Landrigan J; Flynn C; Benjamin GC
    AIDS Public Policy J; 1999; 14(4):147-56. PubMed ID: 11148945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some ethical issues associated with HIV vaccine trials.
    Novick A
    AIDS Public Policy J; 1988; 3(3):46-8. PubMed ID: 11650102
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users.
    Golub ET; Purvis LA; Sapun M; Safaeian M; Beyrer C; Vlahov D; Strathdee SA
    AIDS Behav; 2005 Sep; 9(3):301-9. PubMed ID: 16088366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Willingness to participate in HIV vaccine research in a peri-urban South African community.
    Smit J; Middelkoop K; Myer L; Seedat S; Bekker LG; Stein DJ
    Int J STD AIDS; 2006 Mar; 17(3):176-9. PubMed ID: 16510005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIDS and insurance: the case against HIV antibody testing.
    Scherzer M
    AIDS Public Policy J; 1987; 2(1):19-24. PubMed ID: 11650060
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccine trial needs subjects.
    AIDS Patient Care STDS; 2002 May; 16(5):244. PubMed ID: 12058702
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of the knowledge and beliefs of Finnish medical students regarding HIV infection and participation in AIDS vaccine trials.
    Onigbogi OO; Kauhanen J; Miettola EJ
    Int Q Community Health Educ; 2005-2006; 24(2):123-34. PubMed ID: 17686682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?
    Newman PA; Duan N; Rudy ET; Anton PA
    AIDS Patient Care STDS; 2004 Dec; 18(12):691-701. PubMed ID: 15659880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.